Wizocid 40mg Injection contains Pantoprazole, a proton pump inhibitor (PPI) used to reduce gastric acid secretion. It is indicated for the treatment of gastroesophageal reflux disease (GERD), erosive esophagitis, Zollinger-Ellison syndrome, and other conditions involving excessive stomach acid production. Pantoprazole acts by selectively inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, thereby suppressing the final step of acid production. This results in a significant and prolonged reduction of gastric acid secretion, promoting healing of acid-related damage and alleviating symptoms such as heartburn and acid regurgitation. Wizocid 40mg Injection is administered intravenously, typically reserved for patients who are unable to take oral medication or require rapid acid suppression. The dosage and duration of therapy depend on the clinical condition and patient response. Common adverse effects may include headache, diarrhea, nausea, and injection site reactions. Caution is advised in patients with liver impairment, and long-term use should be monitored for potential risks such as vitamin B12 deficiency or hypomagnesemia. Wizocid 40mg Injection should be used under medical supervision, with attention to contraindications and possible drug interactions.